0.01
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vitasora Health
Its shares trade on ASX under the ticker VHL.AX. It has been listed since 14 July 2000. In the fiscal year to 30 June 2026, it reported revenue of A$4.3m and a net loss of A$10.6m. At that date it held total assets of A$18.8m and shareholders' equity of A$16.1m.
Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-07-14. The firm's segments include Australia and Israel. The Australia segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Israel. The firm's devices and applications use digital wheeze detection and measurement technology. The firm's acoustic respiratory monitoring (ARM) technology records airway sounds to detect continuous adventitious breath sounds (CABS), and measures the extent of wheezing caused by airway obstruction. The firm's products include AirSonea, SonoSentry, Wholter and PulmoTrack Computerised Wheeze Detection.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 14 Jul 2000
- Employees
- 2
- Website
- respiri.com.au ↗
Leadership
Pay as last reported
- Mr. Nicholas SmedleyExecutive Chairman of the Board, since 2019A$355,525
- Mr. Marjan MikelChief Executive Officer, Managing Director, Executive Director, since 2019A$607,296
- Mr. Peter HildebrandtChief Operating OfficerA$292,797
- Mr. George VlachodimitropoulosChief Technology OfficerA$236,476
- Mr. Theo AntonopoulosChief Commercial OfficerA$313,051
- Dr. Samaneh ShiraziChief Research OfficerA$194,104
- Mr. Justin MouchaccaJoint Company Secretary
- Ms. Nova TaylorJoint Company Secretary
- Mr. Jonathan AdamsNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has a focused product portfolio including AirSonea, SonoSentry, Wholter, and PulmoTrack.
- Operates in both Australia and Israel with segments for research and commercialization.
- Uses digital wheeze detection and ARM technology for respiratory monitoring.
Weaknesses
- Only two full-time employees limit operational capacity.
- IPO date of 2000-07-14 suggests a long history but limited recent growth.
- Website domain respiri.com.au may indicate limited brand recognition.
Opportunities
- Expanding into new markets for respiratory disease management solutions.
- Leveraging digital wheeze detection technology for broader health applications.
- Potential partnerships with healthcare providers in Australia and Israel.
Threats
- Limited employee count may hinder scalability and innovation.
- Dependence on a niche market for respiratory devices and apps.
- Competition from larger health tech companies in the medical device sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.